The Safety & Interaction Brief

The Blueprint answers “does it work?” This brief answers the two questions a careful physician actually asks about a formula of this size: are the ingredients safe, and how do they interact — with each other, and with the medications a person in their late 50s–60s is likely already taking. It is deliberately candid: on a formula this considered, the honest answer isn’t “there are no interactions,” but “here are the ones that are real, here is their size, and here is how the product’s design already contains them.” Exact per-ingredient doses are reserved for the confidential physician dossier, not shown here. Nothing here is a health claim or a substitute for individualized clinical judgment.

The list is shorter than it looks

Six rational systems, not forty random actives

The daily sachets are comprehensive, not exotic. Sorted by what the ingredients actually are, the formula collapses into six systems any physician already recognizes:

So the interaction question narrows to a short list of actors — the rest of this brief.

Safety is engineered into the product

Interaction management, built in — not bolted on

• AM/PM temporal separation. Activating/vascular actives in the morning; calming/repair actives at night — halving simultaneous exposure.
• “Complete” vs. “Foundation” — proactive de-prescribing. The entire nitric-oxide module (L-arginine, L-citrulline, pine bark, and the icariin in epimedium) is removed in Foundation for anyone on PDE5 inhibitors, nitrates, or any antihypertensive. The single most important interaction — additive hypotension — self-selects at-risk users out of it.
• Cycling & isolation of the strongest actors. High-dose senolytic fisetin (3 days/month), D-aspartic acid (seasonal), mucuna/L-DOPA (cycled, separated), and berberine (a standalone SKU with a mandatory advisory) are deliberately not in the daily stack.
• Standardized forms; piperine deliberately excluded. Curcumin is a self-bioavailable branded form without black-pepper piperine — removing the most common hidden driver of supplement–drug interactions (CYP3A4 / P-gp).

Individual ingredients to note

The honest short list

Most of the formula (micronutrients, the plant collagen system, most adaptogens, the NAD⁺ core) is benign at these doses. The ingredients a physician should actually flag:

• Ashwagandha. The best-supported single caution — rare idiosyncratic hepatotoxicity (LiverTox), and mild thyrotropic effect. Manage: thyroid advisory (on-label); baseline/periodic LFTs reasonable; caution in liver disease.
• Schisandra (standardized). At this higher dose, its lignans are meaningful CYP3A4 inhibitors — they can raise levels of CYP3A4-metabolized drugs (certain statins, immunosuppressants, some others). Manage: the CYP3A4 advisory is on-label; disclose with narrow-therapeutic-index CYP3A4 drugs.
• DHEA (women, low dose). A low, gated hormone precursor — contraindicated in hormone-sensitive cancer/estrogen-sensitive conditions. Manage: physician advisory; excluded from Foundation.
• Vitamin K2 (MK-7, 200 µg). Benign alone and beneficial for arterial/bone calcium — but a decisive interaction with warfarin (§4.1).
• Creatine (companion). One of the most-studied, safest supplements; the only notes are adequate hydration and caution in significant kidney disease. Manage: on-label hydration/kidney advisory.

Frequently over-worried, reassuring here: NMN (regulatorily settled, cleared as a lawful US dietary ingredient in 2025; no meaningful interaction profile); NAC, spermidine, resveratrol, CoQ10, sulforaphane, the plant collagen builders (gotu kola, amla, proline, manganese), glycine, PHGG, the B-vitamins, and balanced zinc/copper — all low-risk at these doses.

Drug interactions, by the medications a 60-year-old takes

Clustered by drug class, not 70 × N permutations

Anticoagulants & antiplatelets — the most important category

Two real mechanisms, opposite in direction. (1) Vitamin K2 (MK-7) directly antagonizes warfarin — cumulative, with a hard incompatibility at 200 µg (no meaningful effect on DOACs). (2) An additive antiplatelet load from several mild individual inhibitors: resveratrol, quercetin, curcumin, ginger, reishi, omega-3, vitamin E, NAC. Manage: on warfarin/VKA, avoid K2-containing SKUs and coordinate INR — this population is best served by a stripped, supervised version; on DOACs/aspirin, the additive effect is modest but real — disclose, and pause the antiplatelet-active ingredients before surgery/procedures.

Antihypertensives, nitrates & PDE5 inhibitors

The NO module (L-arginine, L-citrulline, pine bark) plus epimedium’s icariin can add to vasodilation/hypotension and potentiate PDE5 drugs/nitrates. Manage: fully handled by Foundation, which removes exactly these ingredients. (And with Coleus/forskolin now cut, the last stray vasodilator is gone.)

Statins & the CYP3A4 question

CoQ10 is beneficial here — it replaces statin-depleted CoQ10. The CYP3A4 actors to disclose are berberine (gated standalone) and Schisandra — both can raise levels of CYP3A4-metabolized statins/immunosuppressants. The deliberate exclusion of piperine removes the single biggest amplifier. Manage: patients on narrow-therapeutic-index CYP3A4 drugs should disclose; the Schisandra advisory is on-label.

Antidiabetics & thyroid

Glucose-lowering is additive from gynostemma (gentle daily AMPK) and, if opted-in, berberine (stronger) — monitor glucose in patients on sulfonylureas/insulin. Ashwagandha may raise thyroid hormone — the thyroid advisory is on-label; monitor TFTs on thyroid medication. (Sulforaphane’s cruciferous origin raises a theoretical goitrogen question only at food-excess intakes; not a concern at the formula dose.)

Antidepressants / Parkinson’s

MAO inhibitors + mucuna (L-DOPA) is a true contraindication (hypertensive-crisis risk); do not combine with prescription levodopa, and use serotonergic caution with SSRIs/SNRIs. Mucuna is cycled/isolated, but this contraindication must be explicit on the Cycle-W label. (St. John’s wort — the classic CYP inducer — is deliberately absent.)

Formula-internal interactions

Mostly benign or already engineered around

• Zinc : copper — the classic long-term concern is pre-empted; copper is included to hold the ratio.
• Alpha-lipoic acid + minerals — ALA chelates zinc/boron, so it was moved to the PM sachet to protect AM mineral absorption.
• Additive CNS calming (PM) — glycine, L-theanine, magnesium, phosphatidylserine, Suan Zao Ren, reishi, ashwagandha are individually mild but additive; combined with alcohol or sedatives the effect compounds. Managed by the “half serving, don’t drive, no alcohol/sedatives” advisory. (Note: GABA and taurine were removed — the PM cluster is now smaller.)
• Beneficial synergies — vitamin C + E regeneration; K2 + D3 calcium handling; the collagen cofactors (C, Cu, Zn, Si, Mn) working with glycine/proline. Coherent by design.
• No supplemental iron — appropriately absent, avoiding pro-oxidant and absorption conflicts.

Bottom line — what to put in front of a prescriber

This is rational polypharmacy, not a random pile. The ingredients with genuine interaction weight are, by design, the ones the product removes for at-risk users (NO module → Foundation), isolates and gates (berberine, mucuna, DAA, fisetin), or standardizes to remove the amplifier (piperine-free). The residual real interactions are a short, specific list.

Sensible monitoring for a healthy 60-year-old cleared to proceed: baseline and ~12-week LFTs (ashwagandha); blood pressure (NO module / orthostasis); TFTs if on thyroid medication; glucose if diabetic and opting into berberine; INR only if ever anticoagulated (in which case, see #1). One deliverable that satisfies most physicians: a single-page “Tell Your Prescriber” card (below) — the SKU taken, the six non-negotiables, and the note to disclose before any surgery/procedure.

“Tell Your Prescriber” card

Interaction matrix — the actors only

Everything not listed carries no material interaction concern at these doses

Prepared to support physician review of the Live by Design · Shine — Rise & Renew formulation. Not medical advice, not a health claim; final labeling and any claims remain governed by qualified regulatory counsel.